Obesity | Jotup

American Liver Foundation Mourns the Passing of Congressman Donald Payne, Jr.

Retrieved on:

Wednesday, April 24, 2024

Obesity, Diabetes, Family, Patient, Liver, Kidney, Liver disease, News, American Liver Foundation

FAIRFIELD, N.J., April 24, 2024 /PRNewswire/ -- Today, American Liver Foundation mourns the passing of a leader on Capitol Hill, the Honorable Donald Payne, Jr, (D-NJ). A champion for patients affected by diabetes, obesity, kidney and liver disease among others, he was devoted to addressing the needs of underserved communities.

Key Points:

FAIRFIELD, N.J., April 24, 2024 /PRNewswire/ -- Today, American Liver Foundation mourns the passing of a leader on Capitol Hill, the Honorable Donald Payne, Jr, (D-NJ).
A champion for patients affected by diabetes, obesity, kidney and liver disease among others, he was devoted to addressing the needs of underserved communities.
American Liver Foundation mourns passing of Congressman Donald Payne, Jr. a champion for patients and the underserved.
"We are so grateful to Congressman Payne for his efforts to support our legislative priorities on behalf of liver patients and are deeply saddened by the unexpected news of his passing."

NABP Report Explores How Illegal Online Sellers Exploit Consumer Demand for Weight Loss Drugs

Retrieved on:

Wednesday, April 24, 2024

Online, Government agency, Risk, Food, Crime, Insurance, Weight loss, Liraglutide, National Association, Obesity, Partnership, Type 2 diabetes, NABP, Organization, Pharmaceutical industry

Unfortunately, because of the drugs' popularity, criminals have seized the opportunity to illegally sell the drugs online, putting patients at risk.

Key Points:

Unfortunately, because of the drugs' popularity, criminals have seized the opportunity to illegally sell the drugs online, putting patients at risk.
NABP's RogueRx Activity Report explores illegal activity that has followed the rise of injectable weight loss drugs.
Illegal online sellers are exploiting this demand by offering substandard and falsified GLP-1 agonists to vulnerable patients.
Learn how you can warn patients against illegal online sellers of GLP-1 agonists by reading the RogueRx Activity Report .

Hanmi Enters into Clinical Trial Collaboration and Supply Agreement with MSD to Evaluate BH3120 in Combination with KEYTRUDA® (pembrolizumab)

Retrieved on:

Wednesday, April 24, 2024

SEOUL, South Korea, April 23, 2024 /PRNewswire/ -- Hanmi Pharmaceutical (KOSPI: 128940, CEO: Jae-Hyun Park), a leading biopharma company in Korea that focuses on research areas such as oncology, obesity/metabolism, and rare diseases, announced it has entered into a Clinical Trial Collaboration and Supply Agreement (CTCSA) with MSD (a tradename of Merck & Co., Inc., Rahway, NJ, USA).

Key Points:

Upon the execution of the agreement, Hanmi Pharmaceutical will conduct a phase 1 clinical trial to evaluate the safety and efficacy of its immuno-oncology drug, 'BH3120', in combination with MSD's anti-PD-1 therapy, KEYTRUDA® (pembrolizumab), in patients with progressive or metastatic solid tumors.
Hanmi Pharmaceutical will sponsor the clinical trial, and MSD will supply KEYTRUDA.
'BH3120' is a next-generation immunotherapy drug that applies 'Pentambody', a bispecific antibody platform technology, currently under joint development by Hanmi Pharmaceutical and its Chinese subsidiary, BJHM (Beijing Hanmi Pharmaceutical).
He said, "Through the collaboration with MSD, we expect BH3120 in combination with KEYTRUDA could improve outcomes for patients with relapsed or refractory disease."

American College of Lifestyle Medicine supports proposed law requiring protections for children from ultra-processed, sugar-sweetened foods and beverages

Retrieved on:

Tuesday, April 23, 2024

Lifestyle medicine-certified clinicians are trained to apply evidence-based, whole-person, prescriptive lifestyle changes to treat and, when used intensively, often reverse common noncommunicable chronic diseases. Applying the six pillars of lifestyle medicine—a whole-food, plant-predominant eating pattern, physical activity, restorative sleep, stress management, positive social connections and avoidance or minimization of risky substances and behaviors--also provides effective prevention of these conditions.

Key Points:

More than 300 ACLM members are pediatricians, several of whom serve in organization leadership roles.
Lifestyle medicine-certified clinicians are trained to apply evidence-based, whole-person, prescriptive lifestyle changes to treat and, when used intensively, often reverse common noncommunicable chronic diseases.
"We also know that children and adolescents who experience obesity are five times more likely to experience it as adults.
In support of the 2022 White House Conference on Hunger, Health and Nutrition, ACLM is also offering a 5.5-hour complimentary CE/CME introductory course on food as medicine and lifestyle medicine.

Endevica Bio drug candidate shows success in weight loss in new study

Retrieved on:

Tuesday, April 23, 2024

Cancer, Diabetes, Weight loss, ESMO, Research, MC4R, ASCO, Obesity, Patient, Metabolism, Quality of life, Rat, Dietary supplement

Additionally, the treatment of A07D was found to provide durable weight loss even after cessation of treatment – suggesting that this approach avoids the problem of weight loss plateau and weight rebound seen with use of GLP1s alone.

Key Points:

Additionally, the treatment of A07D was found to provide durable weight loss even after cessation of treatment – suggesting that this approach avoids the problem of weight loss plateau and weight rebound seen with use of GLP1s alone.
Results from the study support the idea that weight-regulating effects such as those advanced by Endevica Bio to address conditions such as involuntary cancer-related weight loss, can also be harnessed to regulate weight in several disease areas in which excess weight may be detrimental, including diabetes and obesity.
Meanwhile, Endevica Bio's most advanced drug candidate in the weight modulation space, TCMCB07 (B07), will be entering Phase 2 studies this summer.
"We're thrilled with the research results showing our drug candidate could potentially improve the lives of millions of people who seek to lose weight," said Russell Potterfield, CEO and Executive Chairman of Endevica Bio.

THE PLASTIC INDUSTRY DOESN'T GIVE A FORK ABOUT THE PLANET

Retrieved on:

Tuesday, April 23, 2024

Microplastics, Infertility, Health, Male, ADHD, Obesity, Plastic, Shaw Centre, Cancer

OTTAWA, ON, April 23, 2024 /PRNewswire/ -- EARTHDAY.ORG , is shining a light on the plastic industry and their apparent indifference to the health implications of microplastics and their toxic chemicals.

Key Points:

OTTAWA, ON, April 23, 2024 /PRNewswire/ -- EARTHDAY.ORG , is shining a light on the plastic industry and their apparent indifference to the health implications of microplastics and their toxic chemicals.
"We know that the plastic industry doesn't give a fork about the planet," said Tom Cosgrove, Chief Creative & Content Officer, EARTHDAY.ORG.
"It's time for the plastic industry to come clean – what do they know about microplastics and their impact on human health.
"We are all breathing them in and ingesting them involuntarily, but the industry won't talk about it."

THE PLASTIC INDUSTRY DOESN'T GIVE A FORK ABOUT THE PLANET

Retrieved on:

Tuesday, April 23, 2024

Microplastics, Infertility, Health, Male, ADHD, Obesity, Plastic, Shaw Centre, Cancer

OTTAWA, ON, April 23, 2024 /PRNewswire/ -- EARTHDAY.ORG , is shining a light on the plastic industry and their apparent indifference to the health implications of microplastics and their toxic chemicals.

Key Points:

OTTAWA, ON, April 23, 2024 /PRNewswire/ -- EARTHDAY.ORG , is shining a light on the plastic industry and their apparent indifference to the health implications of microplastics and their toxic chemicals.
"We know that the plastic industry doesn't give a fork about the planet," said Tom Cosgrove, Chief Creative & Content Officer, EARTHDAY.ORG.
"It's time for the plastic industry to come clean – what do they know about microplastics and their impact on human health.
"We are all breathing them in and ingesting them involuntarily, but the industry won't talk about it."

Zealand Pharma Partners with Benchling to Advance R&D of Engineered Peptide Medicines

Retrieved on:

Tuesday, April 23, 2024

Cloud, Digital Science, CMO, Zealand Pharma, CMOS, Innovation, GxP, Research, Nasdaq Copenhagen, Obesity, JMP, DSM-IV codes, Congress Center, SAN, Fine chemical

SAN FRANCISCO and ZURICH, April 23, 2024 /PRNewswire/ -- Today Benchling announced that Zealand Pharma A/S, ("Zealand") a biotechnology company focused on the discovery and development of peptide-based medicines, has selected the Benchling R&D Cloud as its central source of truth for scientific data, collaboration, and insights. Teams across Zealand will use the Benchling R&D Cloud to capture, analyze, and share stability data internally and with their external contract manufacturing organization (CMO) partners, in compliance with GxP.

Key Points:

Teams across Zealand will use the Benchling R&D Cloud to capture, analyze, and share stability data internally and with their external contract manufacturing organization (CMO) partners, in compliance with GxP.
Scientists and partners can't be slowed down by siloed systems or a lack of consistent data," said Ludo Otterbein, Head of IT at Zealand Pharma.
Benchling will provide Zealand with the digital data foundation that helps us safely and confidently scale new use cases and partners."
"Benchling R&D Cloud gives Zealand the modern technology to streamline and accelerate its development, compliance, and partner needs.

MUSCLE CULTIVATION STARTUP PROFUSE-TECHNOLOGY WELCOMES RENOWNED TECHNION PROFESSOR TO ITS SCIENTIFIC ADVISORY BOARD

Retrieved on:

Monday, April 22, 2024

Diabetes, Biomedical engineering, Weight loss, Research, Duchenne, Weizmann Institute of Science, Obesity, Biomedicine, Therapy, Cachexia, Patient, Tissue engineering, Regenerative medicine, Sarcopenia, Duchenne muscular dystrophy, Faculty, Ageing, Biotechnology, Pharmaceutical industry

YOKNEAM, Israel, April 22, 2024 /PRNewswire/ -- ProFuse Technology expands its scope as a muscle cultivation startup aiming to enhance patient outcomes by improving treatments for muscle associated diseases and muscle regeneration. The company has appointed Professor Shulamit Levenberg of the Technion Faculty of Biomedical Engineering to its Scientific Advisory Board, to support its effort towards life science applications.

Key Points:

YOKNEAM, Israel, April 22, 2024 /PRNewswire/ -- ProFuse Technology expands its scope as a muscle cultivation startup aiming to enhance patient outcomes by improving treatments for muscle associated diseases and muscle regeneration.
The company has appointed Professor Shulamit Levenberg of the Technion Faculty of Biomedical Engineering to its Scientific Advisory Board, to support its effort towards life science applications.
She has joined ProFuse Technology's Scientific Advisory Board to bolster the company's effort to develop materials and methodologies for muscle regeneration and maintenance.
We are thrilled to welcome Professor Levenberg's to our Scientific Advisory Board, in order to bolster our pioneering innovative approaches towards muscle regeneration and maintenance."

Grocery Shopping Behavior Changes Before and After the COVID-19 Vaccine

Retrieved on:

Monday, April 22, 2024

Transfer, Obesity, Iowa State University, Interview, EBT, COVID-19, Research, Michigan State University, Policy

MILWAUKEE, April 22, 2024 /PRNewswire-PRWeb/ -- In March of 2023, many of the food assistance plans that were implemented due to the pandemic were lifted. In a new paper, Electronic Benefit Transfer (EBT) users increased their grocery spending during the pandemic, which can likely be attributed to the pandemic-era increases in benefits. Many of these households have now lost a substantial amount of benefits, and understanding the effects of decreasing the benefits could have important policy implications.

Key Points:

In the new article "Grocery Shopping Behavior Changes Before and After the COVID-19 Vaccine" published in the Applied Economic Perspectives & Policy, Katie Harris-Lagoudakis from Iowa State University, Hannah Wich from Stephen F. Austin State University, along with Michael Conlin, Cara Haughey, and Seung Yeon Jung from Michigan State University find out how the COVID-19 pandemic has changed grocery shopping behaviors.
The authors say, "As many people intuitively understand, the pandemic accelerated adoption of online grocery shopping through curbside or delivery.
Recent policy changes allow retailers to accept EBT online, and it would be interesting for future research to determine if EBT users are switching to online shopping."
Researchers may want to consider alternate mechanisms to explain increases in obesity, like changes in food-away-from-home purchases or increases in stress."